WallStreetZenWallStreetZen

NASDAQ: KALV
Kalvista Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for KALV

Based on 3 analysts offering 12 month price targets for Kalvista Pharmaceuticals Inc.
Min Forecast
$24.00+366.02%
Avg Forecast
$28.67+456.64%
Max Forecast
$32.00+521.36%

Should I buy or sell KALV stock?

Based on 3 analysts offering ratings for Kalvista Pharmaceuticals Inc.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their KALV stock forecasts and price targets.

KALV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
SVB Leerink
Bottom 6%
6
BuyMaintains$30.00+482.52%2022-10-05
Needham
Top 19%
82
BuyMaintains$24.00+366.02%2022-10-04
Stifel Nicolaus
Bottom 11%
11
Strong BuyMaintains$32.00+521.36%2022-06-08

1 of 1

Forecast return on equity

Is KALV forecast to generate an efficient return?
Company
-27.95%
Industry
22.46%
Market
122.06%
KALV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KALV forecast to generate an efficient return on assets?
Company
-25.23%
Industry
13.57%
KALV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KALV earnings per share forecast

What is KALV's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$4.28
Avg 2 year Forecast
-$3.93
Avg 3 year Forecast
-$1.87

KALV revenue forecast

What is KALV's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$17.0M
Avg 2 year Forecast
$14.0M
Avg 3 year Forecast
$77.7M

KALV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KALV$5.15$28.67+456.64%Strong Buy
CRMD$3.07$14.00+356.03%Strong Buy
STTK$2.97$18.50+522.90%Strong Buy
GLSI$9.96$78.00+683.13%Strong Buy
TNYA$3.10$27.50+787.10%Strong Buy

Kalvista Pharmaceuticals Stock Forecast FAQ

Is Kalvista Pharmaceuticals Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: KALV) stock is to Strong Buy KALV stock.

Out of 3 analysts, 1 (33.33%) are recommending KALV as a Strong Buy, 2 (66.67%) are recommending KALV as a Buy, 0 (0%) are recommending KALV as a Hold, 0 (0%) are recommending KALV as a Sell, and 0 (0%) are recommending KALV as a Strong Sell.

If you're new to stock investing, here's how to buy Kalvista Pharmaceuticals stock.

What is KALV's earnings growth forecast for 2023-2025?

(NASDAQ: KALV) Kalvista Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.86%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.88%.

Kalvista Pharmaceuticals's earnings in 2022 is -$89,272,000.On average, 5 Wall Street analysts forecast KALV's earnings for 2023 to be -$105,296,658, with the lowest KALV earnings forecast at -$118,089,710, and the highest KALV earnings forecast at -$90,043,404. On average, 3 Wall Street analysts forecast KALV's earnings for 2024 to be -$96,685,950, with the lowest KALV earnings forecast at -$125,470,317, and the highest KALV earnings forecast at -$75,528,211.

In 2025, KALV is forecast to generate -$46,005,783 in earnings, with the lowest earnings forecast at -$103,820,537 and the highest earnings forecast at -$15,745,295.

What is KALV's revenue growth forecast for 2023-2025?

(NASDAQ: KALV) Kalvista Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 23.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.53%.

Kalvista Pharmaceuticals's revenue in 2022 is $0.On average, 1 Wall Street analysts forecast KALV's revenue for 2023 to be $417,250,310, with the lowest KALV revenue forecast at $417,250,310, and the highest KALV revenue forecast at $417,250,310. On average, 2 Wall Street analysts forecast KALV's revenue for 2024 to be $344,797,352, with the lowest KALV revenue forecast at $140,969,592, and the highest KALV revenue forecast at $548,625,113.

In 2025, KALV is forecast to generate $1,912,315,248 in revenue, with the lowest revenue forecast at $396,092,570 and the highest revenue forecast at $3,058,031,459.

What is KALV's forecast return on assets (ROA) for 2023-2025?

(NASDAQ: KALV) forecast ROA is -25.23%, which is lower than the forecast US Biotechnology industry average of 13.57%.

What is KALV's Price Target?

According to 3 Wall Street analysts that have issued a 1 year KALV price target, the average KALV price target is $28.67, with the highest KALV stock price forecast at $32.00 and the lowest KALV stock price forecast at $24.00.

On average, Wall Street analysts predict that Kalvista Pharmaceuticals's share price could reach $28.67 by Oct 5, 2023. The average Kalvista Pharmaceuticals stock price prediction forecasts a potential upside of 456.64% from the current KALV share price of $5.15.

What is KALV's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: KALV) Kalvista Pharmaceuticals's current Earnings Per Share (EPS) is -$3.64. On average, analysts forecast that KALV's EPS will be -$4.28 for 2023, with the lowest EPS forecast at -$4.80, and the highest EPS forecast at -$3.66. On average, analysts forecast that KALV's EPS will be -$3.93 for 2024, with the lowest EPS forecast at -$5.10, and the highest EPS forecast at -$3.07. In 2025, KALV's EPS is forecast to hit -$1.87 (min: -$4.22, max: -$0.64).

What is KALV's forecast return on equity (ROE) for 2023-2025?

(NASDAQ: KALV) forecast ROE is -27.95%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.